Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial

MT Newswires Live

06/15

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.

The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.

The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.

The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2643275959"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643275959\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643275959?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643275959","market":"sh","top_or_hot":-1,"title":"Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.</p><p>The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.</p><p>The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.</p><p>The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.</p><p>The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.</p><p>The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.</p><p>The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643275959","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643275959","pubTimestamp":1781510444,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mirum Pharmaceuticals  and Incyte  said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","MIRM":"Mirum Pharmaceuticals, Inc.","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","INCY":"因塞特医疗"},"translate_title":"Mirum Pharmaceuticals和Incyte表示，Zilurgisertib在临床试验期间显示出异位骨化病变体积的显着减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1,"INCY":1.5},"content_text":"Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}